Yasemi̇n Kemal

机构：Samsun University, Istanbul University · ORCID：0000-0002-1175-9085

发表论文 62 篇 · 总被引 653 次 · h-index 12

代表论文

• Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial (2025 · The Lancet · 被引 87)
• Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer (2025 · New England Journal of Medicine · 被引 55)
• Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. (2025 · Journal of Clinical Oncology · 被引 31)
• Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group (2022 · Journal of Cancer Research and Clinical Oncology · 被引 15)
• Major and minor salivary gland cancers: A multicenter retrospective study (2023 · Head & Neck · 被引 12)
• Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non‐small‐cell lung cancer treated with chemoradiotherapy (2021 · Journal of Medical Imaging and Radiation Oncology · 被引 12)